Top 3 Australian AI Healthcare Stocks To Watch In September 2026

Global services activity is holding up even as other parts of the world economy look uneven. That is important for Australian healthcare stocks using artificial intelligence, because hospitals and clinics rely on steady service demand when adopting new tools. Investors watching this shift may not want to wait on the sidelines. This article highlights three Transformative AI Healthcare Stocks from the screener that could help you explore the theme.

The three stocks profiled below are just a starting sample from this Transformative AI Healthcare Stocks idea, and the full screen surfaced 3 more companies with equally compelling narratives that are not covered in the article. If you want to identify your own highest conviction angles on this theme, head straight into the Transformative Artificial intelligence (AI) Healthcare Stocks screener.

ImExHS (ASX:IME)

Overview: ImExHS is a Sydney based company that sells cloud medical imaging software such as its AQUILA radiology platform, along with cardiology and pathology systems, while also running radiology and teleradiology services that generate the scans and reports used to train and deploy AI diagnostic tools. This combination of software and imaging services gives ImExHS a direct role in bringing AI assisted diagnostics into everyday hospital and clinic workflows.

Operations: ImExHS generates about A$10 million from Software and A$21 million from Radiology, with virtually all of its roughly A$31 million revenue coming from Latin America.

Market Cap: A$19 million

ImExHS gives you exposure to AI in healthcare where it is already being applied, at the coalface of medical imaging workflows. The AQUILA platform and teleradiology services create a rich pipeline of scans and radiologist reports that can feed AI diagnostic tools. The latest half year results show a move from a A$3 million loss to a small profit, and guidance points to mid single to mid teens revenue growth for 2026. On the other hand, the company is small, carries higher risk external borrowing and has a high P/E, so any stumble in software uptake or AI roll out could affect sentiment significantly. For investors who can handle that volatility, there is more to unpack beneath the headline numbers and product labels.

ImExHS is already wiring AI into real world imaging workflows, and the real story may be how its small profit, higher P/E and leverage fit together in the 2 key rewards and 1 important warning sign

Singular Health Group (ASX:SHG)

Overview: Singular Health Group is a Leederville based healthcare technology company that turns CT, MRI and PET scans into 3D models and delivers its AI in the Cloud service, which applies AI models to those images to support diagnostics and image analysis, alongside a broader 3DICOM software suite for clinicians, educators and patients.

Market Cap: A$60 million

Investors interested in how AI can change medical imaging may want Singular Health Group on their radar, because its AI in the Cloud service is directly aimed at improving how CT, MRI and PET scans are interpreted rather than just handling storage and file transfer. Revenue is still small at about A$1.43 million and the company reported a loss of A$6.34 million in the 2026 financial year, so this is firmly an early stage, higher risk story, with less than a year of cash runway and reliance on external funding. The question is whether that focused AI imaging push and experienced board can turn today’s spend into a more substantial commercial footprint before the balance sheet needs a reset.

Singular Health Group is pushing hard on AI imaging while the small A$1.43 million revenue base and recent A$6.34 million loss keep many investors cautious. Before you decide it is too early or too risky, walk through the Singular Health Group financial health report

Artrya (ASX:AYA)

Overview: Artrya is a West Perth based medtech company that has built Salix, a cloud AI platform that reads coronary CT angiography scans to help clinicians detect coronary artery disease and identify patients at risk of a heart attack. The focus is on using artificial intelligence to sharpen cardiac diagnostics and risk stratification, which is a direct fit with the AI in healthcare theme.

Operations: Artrya currently generates about A$0.03 million in revenue from developing its AI driven coronary CT image analysis technology, all from Australia.

Market Cap: A$681.2 million

Artrya puts AI directly into the high stakes task of spotting heart attack risk, which is why many investors are watching Salix as CCTA and plaque assessment gain traction with major US insurers. The company is still very early, with only A$0.03 million of sales and a recent A$25.18 million loss. The real question is whether its strong cash position, SAPPHIRE real world study and potential third Flow module can close the gap between ambition and current receipts. For anyone interested in AI diagnostics, the mix of large addressable scan volumes, regulatory and clinical hurdles, insider dilution and a focused coronary niche makes Artrya a story worth watching closely rather than a simple yes or no.

Artrya’s early revenue and recent A$25.18 million loss can make the story look stalled; however, its coronary AI focus could be building towards an inflection point that the analyst forecasts for Artrya hints at but does not fully spell out

Seeking Fresh Angles Beyond Healthcare AI?

Some of the fastest moving ideas are still under the radar for now. Screens update, momentum shifts and ideal entry points can appear and disappear quickly.

• Spot companies building steady momentum and cash strength with a curated list of solid balance sheet and fundamentals (21 results) before the crowd focuses on similar opportunities.
• Explore potential breakout cycles in precious metals producers by scanning the hand picked 35 elite gold producer stocks while valuations remain aligned with recent sentiment.
• Track businesses supporting AI’s physical backbone through a focused 55 AI infrastructure stocks to monitor infrastructure demand as it gains broader attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com